Joinn Laboratories(China)Co.,Ltd.
603127
Rank in Stocks
#3810
Joinn Laboratories (China) Co., Ltd. delivers a comprehensive suite of... Joinn Laboratories (China) Co., Ltd. delivers a comprehensive suite of preclinical and non-clinical services to clients across the United States, China, and other international regions. The company's business is organized into three core operational areas. Its Non-Clinical Studies Services segment focuses on drug safety assessment, drug metabolism and pharmacokinetics analysis, and pharmacology and efficacy investigations. The Clinical Trial and Related Services division offers contract research organization (CRO) support for clinical trials, co-manages Phase I clinical research units, and provides bioanalytical services. Furthermore, the Sales of Research Models segment is involved in the design, production, breeding, and distribution of various research models, including non-human primates and rodents. Beyond these offerings, Joinn Laboratories also provides investment management and cell-based assay (CBA) services. Founded in 1995, the company is headquartered in Beijing, China.
Share Price
$6.82
Market Cap
$4.30B
Change (1 day)
-6.30%
Change (1 year)
48.79%
Country
CN
Trade Joinn Laboratories(China)Co.,Ltd. (603127)
Category
Healthcare
P/E ratio for Joinn Laboratories(China)Co.,Ltd. (603127)
P/E ratio as of October 2026 TTM: 34.33
According to Joinn Laboratories(China)Co.,Ltd. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 34.33. At the end of 2024 the company had a P/E ratio of 166.30.
P/E ratio history for Joinn Laboratories(China)Co.,Ltd. from 2012 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 34.33 | -60.78% |
| 2025 | 87.53 | -47.37% |
| 2024 | 166.30 | 283.88% |
| 2023 | 43.32 | 48.74% |
| 2022 | 29.13 | -61.85% |
| 2021 | 76.35 | 2.89% |
| 2020 | 74.21 | 49.15% |
| 2019 | 49.76 | -0.83% |
| 2018 | 50.17 | -1.16% |
| 2017 | 50.76 | 137.01% |
| 2016 | 21.42 | -4.80% |
| 2015 | 22.49 | 0.00% |
| 2014 | 22.49 | -55.00% |
| 2013 | 49.99 | -55.45% |
| 2012 | 112.21 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 36.15 | 5.33% |
US
|
|
| 38.25 | 11.43% |
US
|
|
| -294.36 | -957.57% |
US
|
|
| 18.69 | -45.55% |
CN
|
|
| 34.92 | 1.74% |
US
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.